Crispr Gene-Editing Treatment Could Point Way to Fix for Deadly Aging Disease

  • 📰 WSJ
  • ⏱ Reading Time:
  • 40 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 19%
  • Publisher: 63%

United States Headlines News

United States Latest News,United States Headlines

Scientists using a version of Crispr gene editing succeeded in significantly extending the lives of mice with progeria, a rare rapid-aging disease that in children typically leads to death in their teens

.

The pathbreaking achievement, described in a paper published on Wednesday in Nature, suggests that it may be possible to develop effective treatments not only for progeria but also for“The extension of lifespan in the mice is a stark and compelling result that underscores the potential for these types of technologies to be transformative,” said Charles Gersbach, director of the Duke University Center for Advanced Genomic Technologies, who wasn’t involved in the progeria study.

The experimental technique, known as base editing, involves changing or editing a single base pair of letters that form the rungs of the ladderlike DNA molecules that make up human and animal genomes. Crispr was first used for gene editing in 2012, and base editing was developed in 2016.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

..lovely boy Smart to Potato is potato Pop corn are for Indian... ..he pens!!

Really a most insidious disease and if there's a cure on the horizon every resource should be made available.

I wish there were a way to have more scientists, working on this and that once a cure found, it could be fast tracked. What a ❤️ picture of such a lovely family.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 98. in US

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.